COINFECCIÓN VIH/VHB
FACTORES ASOCIADOS A LA CURA FUNCIONAL DEL VHB
DOI:
https://doi.org/10.54620/cadesp.v19i1.2273Palabras clave:
VIH, Virus de la Hepatitis B, Terapia Antirretroviral Altamente Activa, Antígenos de Superficie de la Hepatitis BResumen
Las investigaciones sobre el VIH siguen siendo frecuentes desde su descubrimiento. La coinfección VIH/VHB tiene gran importancia, ya que impacta la historia natural de la infección crónica por el VHB, aumentando la mortalidad. Objetivo: Identificar la prevalencia de la cura funcional en pacientes con coinfección VIH/VHB y los posibles factores asociados a esta cura. Método: Se trata de una cohorte retrospectiva realizada entre julio de 2023 y agosto de 2024 en dos centros de salud de Fortaleza. Resultados: De los 175 pacientes con coinfección incluidos, solo 146 tuvieron acceso al HBsAg de control. En el análisis comparativo entre los dos grupos, factores como la ausencia de HBeAg positivo y la indetección del ADN del VHB fueron estadísticamente significativos para la negativización del HBsAg. Conclusión: Estos resultados sugieren que un buen control del VHB, especialmente en pacientes con HBeAg negativo, está asociado con una mayor prevalencia de cura funcional.
Descargas
Citas
Ministério da Saúde (BR). Departamento de HIV/Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis Secretaria de Vigilância em Saúde e Ambiente. Boletim Epidemiológico, HIV e AIDS 2024. Brasília, DF, n. esp., p. 1-82, dez. 2024. Disponível em: https://www.gov.br/aids/pt-br/central-de-conteudo/boletins-epidemiologicos/2024/boletim_hiv_aids_2024e.pdf/view.
Pereira AC, Sales WB, Oliveira ASC, Pereira LEA, França JGM. Percepção de enfermeiros frente ao HIV/AIDS: uma revisão integrativa. Cadernos ESP. 2023 Ago;17(1):e841. DOI: https://doi.org/10.54620/cadesp.v17i1.841. DOI: https://doi.org/10.54620/cadesp.v17i1.841
Cock KMD, Jaffe HW, Curran JW. Reflections on 40 Years of AIDS. Emerg Infect Dis. 2021 Jun;27(6):1553–1560. DOI: 10.3201/eid2706.210284. DOI: https://doi.org/10.3201/eid2706.210284
Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Hepatites Virais: 2024. Boletim Epidemiológico, Brasília, DF, n. esp., p. 1-84, jul. 2024. Disponível em: https://www.gov.br/aids/pt-br/central-de-conteudo/boletins-epidemiologicos/2024/boletim-epidemiologico-hepatites-virais-2024/view.
Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, et al. Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis. J Viral Hepat. 2020 Mar;27(3):294-315. DOI: 10.1111/jvh.13217. DOI: https://doi.org/10.1111/jvh.13217
Audsley J, Anchalee A, Littlejohn M, Bowden S, Matthews GV, Fairley CK, et al. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection—Lessons for Functional HBV Cure? J Acquir Immune Defic Syndr. 2020 Aug;84(5):527-533. DOI: 10.1097/QAI.0000000000002386. DOI: https://doi.org/10.1097/QAI.0000000000002386
Távora LGF, Hyppolito EB, Cruz JNM, Portela NMB, Pereira SM, Veras CM. Hepatitis b, c and HIV co-infections seroprevalence in a northeast brazilian center. Arq. Gastroenterol. 2013. 50(4). DOI: https://doi.org/10.1590/S0004-28032013000400007. DOI: https://doi.org/10.1590/S0004-28032013000400007
Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas DL, Flexner C. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. The Lancet HIV. 2020 Jun;7(6):e443–8. DOI: 10.1016/S2352-3018(19)30342-X. DOI: https://doi.org/10.1016/S2352-3018(19)30342-X
Chihota BV, Wandeler G, Chilengi R, Mulenga L, Chung RT, Bhattacharya D, et al. High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia. J Infect Dis. 2020 Jan;221(2):218-222. DOI: 10.1093/infdis/jiz450. DOI: https://doi.org/10.1093/infdis/jiz450
Boyd A, Lorenza, Lacombe K. Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review. Viruses. 2021 Jul;13(7):1341. DOI: 10.3390/v13071341. DOI: https://doi.org/10.3390/v13071341
Ministério da Saúde (BR). Secretaria de Ciência, Tecnologia, Inovação e Complexo da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Protocolo Clínico e Diretrizes Terapêuticas de Hepatite B e Coinfecções, Brasília, DF, p. 1-144, 2023. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_diretrizes_terapeuticas_hepbdigital.pd.
He Y, Lin W, Li H, Gu F, Zhong H, Lan Y, et al. Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China. Chin Med J (Engl). 2023 Nov;136(22):2686-2693. DOI: 10.1097/CM9.0000000000002886. DOI: https://doi.org/10.1097/CM9.0000000000002886
Xia H, Gao L, Hu Y, Huang X, Wu H, Ma P. High rates of hepatitis B virus (HBV) functional cure among HIV/HBV coinfected Chinese adults on antiretroviral therapy. Chin Med J (Engl). 2022 Nov; 135(22):2744–2746. DOI: 10.1097/CM9.0000000000002501. DOI: https://doi.org/10.1097/CM9.0000000000002501
Kathrin van Bremen, Hoffmann C, Mauss S, Lutz T, Ingiliz P, Spinner CD, et al. Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection. Liver Int. 2020 Oct;40(12):2978-2981. DOI: 10.1111/liv.14684. DOI: https://doi.org/10.1111/liv.14684
Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, et al.. Risk of HCC with hepatitis B viremia mong HIV/HBV-Coinfected Persons in North America. Hepatology. 2021 Sep;74(3):1190-1202. DOI: 10.1002/hep.31839. DOI: https://doi.org/10.1002/hep.31839
Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, et al.. Determinants of liver complications among HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr. 2019 Sep;82(1):71–80. Epub 2019/05/21. DOI: 10.1097/QAI.0000000000002094. DOI: https://doi.org/10.1097/QAI.0000000000002094
Vinikoor MJ, Hamusonde K, Muula G, Asombang M, Riebensahm C, Chitundu H, et al. Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia. Clin Infect Dis. 2024 Jun;78(6):1583-1590. DOI: 10.1093/cid/ciad654. DOI: https://doi.org/10.1093/cid/ciad654
Hofmann E, Surial B, Boillat-Blanco N, Günthard HF, Stöckle M, Bernasconi E, et al. Swiss HIV Cohort Study. Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection. Clin Infect Dis. 2023 Feb;76(4):730-733. DOI: 10.1093/cid/ciac823. DOI: https://doi.org/10.1093/cid/ciac823
Jain MK, Vigil KJ, Parisot P, Go G, Vu T, Li X, et al. Incidence and predictors of Hepatitis B Surface Antigen Clearance in HIV Patients: A Retrospective Multisite Study.Open Forum Infect Dis. 2021 July;8(7):ofab116. DOI: 10.1093/ofid/ofab116. DOI: https://doi.org/10.1093/ofid/ofab116
Yeo YH, Ho HJ, Yang HI, Tseng TC, Hosaka T, Trinh HN, et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology. 2019 Feb;156(3):635-646.e9. DOI: 10.1053/j.gastro.2018.10.027. DOI: https://doi.org/10.1053/j.gastro.2019.01.019
Wei H, Jiang HY, Li M, Zhang T, Song B. Two-dimensional shear wave elastography for significant liver fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. Eur J Radiol. 2020 Mar;124:108839. DOI: 10.1016/j.ejrad.2020.108839. DOI: https://doi.org/10.1016/j.ejrad.2020.108839
Archivos adicionales
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2025 Cadernos ESP
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Aceptado 2025-06-04
Publicado 2025-07-09
